Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral glibenclamide for traumatic brain contusion after moderate to severe traumatic brain injury
IRCT20170513033941N45Phase 3Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in traumatic brain injury (TBI) and cerebral contusion comparing Glibenclamide with Placebo (2 arms). Primary endpoint: Brain contusion volume. Started Nov 2018; status: completed.
02
Drugs
glibenclamide
03
Conditions
traumatic brain injury (TBI)cerebral contusion
Beyond the preview
Go deeper on IRCT20170513033941N45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170513033941N45.